TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Recruiting now · Not applicable

Conditions studied: Breast Neoplasm Malignant Primary

In brief

TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.

Key facts

Study ID

NCT06310330

Run by

Norwegian University of Science and Technology

People needed

250

Starts

2024-03-08

Expected to finish

2026-12-31

Last updated by the study team

2025-06-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Breast cancer and referral for follow-up to identify potential CTRCD

You may not qualify if…

• Not willing or able to consent

Where it is running

• St. Olavs hospital — Trondheim, Norway (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.